ALSV
KDNY

ATP Life Science Ventures’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

ATP Life Science Ventures’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,028,937
Closed -$62.6M – 3
2021
Q1 		$62.6M Hold
4,028,937
– – 6.97% 3
2020
Q4 		$63.9M Buy
+4,028,937
New +$60.8M 4.93% 3

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ATP Life Science Ventures's KDNY Position: Q2 2021 in Review

ATP Life Science Ventures sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2021, closing a stake of 4,028,937 shares — an estimated $62.6M sold.

ATP Life Science Ventures first reported a position in KDNY in Q4 2020 and held it in 2 quarters. The position peaked at $63.9M in Q4 2020. 89 funds tracked by Wall St. Rank hold KDNY as of Q2 2021.

  • ATP Life Science Ventures reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • ATP Life Science Ventures sold 4,028,937 Chinook Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $62.6M.
  • ATP Life Science Ventures first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • ATP Life Science Ventures's Chinook Therapeutics, Inc. Common Stock position peaked at $63.9M in Q4 2020.
  • 89 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2021.

Based on ATP Life Science Ventures's 13F filing for Q2 2021.